|
|
Article: Alnylam Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day.
- Article from:
- Business Wire
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Update on Pipeline Includes New Pre-clinical In Vivo Data Demonstrating that ALN-TTR Blocks Pathogenic Tissue Deposition of Mutant TTR Protein by Greater than 95% -
- Update on Delivery Platform Includes Research on Discovery of Novel Lipid Nanoparticles with Improved Gene Silencing Potency at Doses Less than 30 Micrograms per Kilogram -
- Update on Technology Efforts Includes New Data on Applications of RNAi in Biologics Manufacturing, Creating New Business Opportunity -
CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology ...